Nonsurgical lumbar radiculopathies treated with ultramicronized palmitoylethanolamide (umPEA): A series of 100 cases
Case seriesHumans
- Design
- Case series
- Subjects
- 100 patients (73 men, 27 women, aged 45 to 75) with chronic low back pain from degenerative lumbar disease without surgical indication, reviewed retrospectively
- Dose used in the study
- Ultramicronised PEA together with paracetamol and codeine; PEA dose not given in the abstract or preview
- Duration
- Two treatment cycles with checks at one and two months
- What was measured
- Pain on a visual analogue scale
What the authors reported
After one month, mean VAS fell by 1.9, 2.7 and 2.3 points in the mild, moderate and severe baseline groups (p < 0.0001), with further improvement after the second cycle. About 80 percent responded. No adverse effects.
Limits of this study
Retrospective case series with no control group. PEA was given with paracetamol and codeine, so the PEA contribution cannot be separated. PEA dose not stated in the text available.
Source
PubMed 29157720 · doi:10.1016/j.pjnns.2017.11.002
Entry checked against the abstract and preview, supplied by Devlin. PEA dose not in the text available on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.